← Human Trials & Peer-Reviewed Studies
Study protocol: a randomised controlled proof-of-concept real-world study - does maximising time in range using hybrid closed loop insulin delivery and a low carbohydrate diet restore the glucagon response to hypoglycaemia in adults with type 1 diabetes?
Plain-language guide to PMID 36600427 (2022): randomized clinical study of Glucagon.
Key Facts
- PMID
- 36600427
- Journal
- BMJ open
- Year
- 2022
- Study type
- Clinical Study
- Authors
- Baxter F et al. (3 authors)
- DOI
- 10.1136/bmjopen-2021-054958
What This Study Did, in Plain Language
What Was Tested
This clinical study looks at Glucagon.
Participants will have their glucagon response to hypoglycaemia measured at the beginning and 8 months later at the study end using a stepped hyperinsulinaemic hypoglycaemic clamp, in combination with the stable isotopes 6,6-2H2-glucose (D2-glucose) and 1,1,2,3,3-2H5-glycerol (D5-glycerol) to assess glucose and glycerol kinetics.
Why It Was Studied
It is not known whether eliminating hypoglycaemia and hyperglycaemia allows recovery of this glucagon response.
However, post-prandial glycaemic excursions are still evident.
Who Took Part
By PubMed's age tags, the people studied were adults.
Baseline data on diet and glycaemia will be collected from all participants.
How the Study Was Run
In design terms this was a randomized study.
The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.
The HCL-LCD group will then enter a 2-week run-in to acclimatise to their devices.
The impact of hypoglycaemia on symptoms and cognitive function will be assessed during each clamp study.
The primary outcome is the difference in the glucagon response to hypoglycaemia between and within groups at baseline versus study end.
What Was Measured
PubMed files the paper under topics including Diabetes Mellitus, Type 1, Insulin, Glucagon, Blood Glucose Self-Monitoring, Glycerol, Blood Glucose and Insulin Infusion Systems.
Author keywords: DIABETES & ENDOCRINOLOGY, General diabetes, General endocrinology, NUTRITION & DIETETICS, Physiology and Protocols & guidelines.
What This Means in Plain Language
The paper is a randomized study of Glucagon.
The publication is from 2022 (BMJ open), a journal based in England.
More context: the Glucagon compound page, all human trials.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.